Ftse Mib
32.917,87
0,77%
DAX
18.068,21
0,26%
S&P 500
5.487,12
1,02%
NASDAQ
17.913,09
1,27%
Bitcoin
66.879,79
0,36%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ultragenyx Pharmaceutical Inc (RARE) Ultragenyx Pharmaceutical Inc (RARE) Notizie

RARE

Ultragenyx Pharmaceutical (RARE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RARE
DataOraFonteTitoloSimboloCompagnia
17/06/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
14/06/202423:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RAREUltragenyx Pharmaceutical Inc
14/06/202402:49GlobeNewswire Inc.Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
13/06/202401:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202423:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202422:05GlobeNewswire Inc.Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202422:00GlobeNewswire Inc.Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
11/06/202423:47GlobeNewswire Inc.Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
04/06/202422:05GlobeNewswire Inc.Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/05/202422:00GlobeNewswire Inc.Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)NASDAQ:RAREUltragenyx Pharmaceutical Inc
17/05/202422:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
07/05/202422:30GlobeNewswire Inc.Ultragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
02/05/202422:00GlobeNewswire Inc.Ultragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202422:00GlobeNewswire Inc.Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202414:00GlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
25/04/202422:30GlobeNewswire Inc.Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
15/04/202413:00GlobeNewswire Inc.Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102NASDAQ:RAREUltragenyx Pharmaceutical Inc
12/04/202422:22GlobeNewswire Inc.Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/04/202414:00GlobeNewswire Inc.Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
27/02/202422:30GlobeNewswire Inc.Ultragenyx to Participate at Investor Conferences in MarchNASDAQ:RAREUltragenyx Pharmaceutical Inc
21/02/202423:03Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RAREUltragenyx Pharmaceutical Inc
15/02/202422:01GlobeNewswire Inc.Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/02/202422:00GlobeNewswire Inc.Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/02/202414:00GlobeNewswire Inc.Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
05/02/202422:05GlobeNewswire Inc.Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
25/01/202422:05GlobeNewswire Inc.Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
08/01/202413:00GlobeNewswire Inc.Mereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/01/202417:00GlobeNewswire Inc.Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/01/202414:00GlobeNewswire Inc.Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)NASDAQ:RAREUltragenyx Pharmaceutical Inc
03/01/202414:00GlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman SyndromeNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RARE

La tua Cronologia

BIT
P1HWQ6
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network